Biotechnology
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical trial of i...
2026-07-24 09:30
2344
ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406
SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clini...
2026-07-24 09:00
3023
NYSE Content Update: Fourth Annual AI x Bio Summit to Commence at the NYSE
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...
2026-07-23 20:55
3898
PUBLIC TRUST IN HEALTH INNOVATION IS SHAPED MORE BY MINDSET THAN DEMOGRAPHICS, DNV RESEARCH FINDS
OSLO, Norway, July 23, 2026 /PRNewswire/ -- Public trust in health innovation
may be less predictable than healthcare organizations assume, according to new
research from DNV, the independent assurance and certification provider.
2026-07-23 20:34
1988
Moa Technology raises Series C round co-led by Oxford Science Enterprises and Supernova Invest
OXFORD, England, July 23, 2026 /PRNewswire/ -- Moa Technology ("Moa"), an agricultural biotechnology company focused on discovering novel mode of action herbicides, announces a £22.2 million Series C financing round, co-led by Oxford Science Enterprises ("OSE") and Supernova Invest ("Supernova")....
2026-07-23 17:00
2945
GHIT Fund Invests Approx. JPY 140 Million in a Portable Rapid Diagnostic System for Ebola Disease in a Joint Project Between Osaka Metropolitan University, K.K. DNAFORM, and INRB
TOKYO, July 23, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of JPY 140 million (approximately USD 862,000) in a project to develop a portable rapid diagnostic system for Ebola disease. The system is being jointly developed by Osaka Metrop...
2026-07-23 12:01
2202
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model. HONG KONG, July 23, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ...
2026-07-23 08:10
4056
Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive results fro...
2026-07-22 20:28
4491
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors
Funding will support completion of IND-enabling activities and planned year-end
IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate
targeting B7-H3-positive solid tumors
SINGAPORE, July 22, 2026 /PRNewswire/ -- Tikva Allocell Pte. Ltd.
2026-07-22 19:03
3815
LSBF and University of Roehampton Expand Healthcare Education with LSBF Singapore Campus's New School of Health Sciences
SINGAPORE, July 22, 2026 /PRNewswire/ -- London School of Business & Finance (LSBF) Singapore Campus has announced the launch of its School of Health Sciences in 2026, marking a significant milestone in the institution's continued expansion into high-growth industries. Developed in partnership wi...
2026-07-22 15:36
5252
Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026
As a Premier Partner, Gene Solutions presented Asia-led real-world evidence from large-scale NIPT-integrated carrier screening, alongside advances in AI-enabled pregnancy-risk assessment and minimally invasive molecular approaches to women's health. SINGAPORE, July 22, 2026 /PRNewswire/ -- Gene ...
2026-07-22 11:59
3810
NSG Bio Accelerates Breakthrough Biotech Innovation in Singapore
New initiative under NSG Bio Tomorrow will support promising startups developing next-generation approaches in respiratory and neonatal care SINGAPORE, July 22, 2026 /PRNewswire/ -- The NSG Bio Tomorrow initiative aims at supporting emerging life sciences startups working on complex challenges in...
2026-07-22 08:00
2678
Angel Yeast's Initiative Advances Internationally Recognized Codex Standard for baker's yeast
YICHANG, China, July 21, 2026 /PRNewswire/ -- The 49th session of the
Codex Alimentarius Commission (CAC49), held in Geneva, Switzerland, from July 6
to 10, 2026, adopted a number of international food standards, including the
Codex Standard for Baker's Yeast, which was proposed by China.
2026-07-21 20:57
2680
Takeda's Dengue Vaccine (TAK-003) Becomes India's First Approved Dengue Vaccine, Bringing Prevention to One of the World's Most At-Risk Populations
* The approval comes at a critical time for public health, as reported dengue cases in India have increased 11-fold in the past two decades[1] * Takeda's dengue vaccine (TAK-003) is the most extensively studied dengue vaccine, with long-term data demonstrating sustained protection against deng...
2026-07-21 16:41
3692
Haier Biomedical Presents Digital Blood Management Platform at ISBT Congress 2026, Advancing Its Transition from Equipment Provider to Full-Process Solution Partner
Driving Digital Transformation in Blood Management for Plasma Collection
Centers, Hospitals, and Blood Bank Centers
KUALA LUMPUR, Malaysia, July 21, 2026 /PRNewswire/ -- Haier Biomedical
2026-07-21 14:29
3946
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] * Group revenue of US...
2026-07-21 06:52
5941
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
• First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). • LUTEON is the first Phase 3 study of a CAIX[2]-targeted radiopharmaceutical therapy in ccRCC MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire...
2026-07-21 05:00
3709
Generative Bionics Introduces Gene.01, a Fully Functional Smart-Skin Humanoid Robot Platform Designed for Safe Human Collaboration
Built in six months, Gene.01 senses touch, proximity, force, and temperature, and it is released with its open-sourced robot model that gives Physical AI developers a shared starting point to build industrial applications Key Highlights * Fastest-ever transition to a functional humanoid: Gene....
2026-07-20 20:00
4487
Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
* DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1 * Broadest pivotal trial to date, enrolling patients with a wide range of DEE syndromes, the majority...
2026-07-20 16:20
3506
Medtrum Advances 300U Tubeless Patch Pump Toward German Launch
Higher-capacity option expands the TouchCare Nano System and supports Medtrum's continued growth in Europe BERLIN, July 20, 2026 /PRNewswire/ -- Medtrum, a global diabetes technology company, today announced further progress toward the German launch of its 300-unit (300U) tubeless patch pump, fo...
2026-07-20 15:05
2163
Week's Top Stories
Most Reposted
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 275 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 270 media titles]
2026-10-22 11:55Carro Establishes Inaugural SGD450 Million Asset-Backed Securitisation Warehouse Facility
[Picked up by 267 media titles]
2026-10-22 11:00Ready Server Launches ReadyServer LLM API, Giving Every VPS Customer Private AI Inference at No Extra Cost
[Picked up by 265 media titles]
2026-10-20 14:10Most Read
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
2026-10-19 13:18
10862
FinDev Canada provides a USD 60 million loan to Muangthai Capital to advance gender equality and private sector investment in Thailand
2026-10-17 00:54
10691
BUUU Group Limited Announces 10-for-1 Forward Share Split
2026-10-17 04:30
10020